Treatment-Induced Changes in Plasma Adiponectin Do Not Reduce Urinary Albumin Excretion in the Diabetes Prevention...

Area of Science:

• Endocrinology
• Nephrology
• Metabolic Syndrome

Background:

• Adiponectin, a key metabolic hormone, is implicated in regulating urinary albumin excretion.
• Previous findings suggested interventions in the Diabetes Prevention Program (DPP) increased adiponectin levels.
• The role of adiponectin in albuminuria, particularly in obesity, requires further investigation.

Purpose of the Study:

• To test the hypothesis that treatment-induced increases in adiponectin reduce albuminuria in obese individuals.
• To evaluate the relationship between adiponectin and albuminuria at baseline and after intervention within the DPP cohort.

Main Methods:

• Cross-sectional analysis of baseline correlations between plasma adiponectin and urinary albumin to creatinine ratio (ACR).
• Longitudinal analysis of treatment-related changes in adiponectin and ACR in 2553 DPP participants.
• Statistical adjustments for age, sex, and race/ethnicity.

Main Results:

• A weak, statistically significant inverse association was observed between adiponectin and ACR at baseline.
• DPP interventions significantly increased plasma adiponectin but did not affect ACR.
• No significant differences in ACR were found across treatment groups, and changes in adiponectin did not correlate with reduced albuminuria.

Conclusions:

• Treatment-related increases in adiponectin were not associated with reduced albuminuria in this cohort of obese, dysglycemic subjects.
• The findings do not support the hypothesis that increasing adiponectin reduces albuminuria in this population.
• Further studies in populations with overt albuminuria are warranted to fully elucidate adiponectin's role in reducing albuminuria.